PH94B
Phase 3Terminated 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Social Anxiety Disorder
Conditions
Social Anxiety Disorder
Trial Timeline
Oct 1, 2021 → Sep 23, 2022
NCT ID
NCT05030350About PH94B
PH94B is a phase 3 stage product being developed by Vistagen Therapeutics for Social Anxiety Disorder. The current trial status is terminated. This product is registered under clinical trial identifier NCT05030350. Target conditions include Social Anxiety Disorder.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05030350 | Phase 3 | Terminated |
Competing Products
20 competing products in Social Anxiety Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY686017 + paroxetine + placebo | Eli Lilly | Phase 2 | 52 |
| atomoxetine + placebo | Eli Lilly | Phase 2/3 | 65 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 52 |
| Cariprazine + Placebo | AbbVie | Approved | 85 |
| Quetiapine | AstraZeneca | Approved | 85 |
| quetiapine | AstraZeneca | Phase 3 | 77 |
| quetiapine | AstraZeneca | Phase 2/3 | 65 |
| Seroquel + Sugar Pill | AstraZeneca | Phase 3 | 77 |
| quetiapine | AstraZeneca | Approved | 85 |
| Pristiq + Placebo | Pfizer | Approved | 84 |
| Venlafaxine ER | Pfizer | Phase 3 | 76 |
| Ziprasidone + Sertraline | Pfizer | Phase 2 | 51 |
| Sertraline + Placebo | Pfizer | Approved | 84 |
| Nefazodone | Bristol Myers Squibb | Approved | 84 |
| Escitalopram | Lundbeck | Approved | 82 |
| Cipralex + Placebo | Lundbeck | Phase 2 | 49 |
| BHV-0223 + Placebo | Biohaven | Phase 2/3 | 60 |
| VQW-765 + Placebo | Vanda Pharmaceuticals | Phase 3 | 69 |
| Fasedienol Nasal Spray - Placebo Nasal Spray + Fasedienol Nasal Spray - Fasedienol Nasal Spray + Placebo Nasal Spray - Placebo Nasal Spray | Vistagen Therapeutics | Phase 2 | 44 |
| PH94B Nasal Spray + Placebo Nasal Spray | Vistagen Therapeutics | Phase 3 | 69 |